Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Chris Markoch

Amgen Drops 10% on a Trial It Didn't Even Run

Amgen Inc. (NASDAQ: AMGN) delivered a strong earnings report on Aug. 4. AMGN stock rose approximately 17% from the Aug. 4 close through early September before reversing sharply.

One of the highlights of Amgen’s report was Repatha, Amgen's approved PCSK9 drug, which posted $953 million in Q2 2026 revenue, a 37% year-over-year increase. But those gains have mostly been erased due to what can only be labeled as guilt by association.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.